Phase 3Withdrawn

Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)

A Randomized, Double-blind, Placebo- and Active- Controlled, Multicenter Study of Rapastinel as Monotherapy in Major Depressive Disorder

Sponsor
Naurex, Inc, an affiliate of Allergan plc (Industry)
Conditions
Depressive Disorder, Major
Interventions
Rapastinel; Vortioxetine; Placebo
Ages
adults, older adults
Registry
NCT03855865, EUCTR2018-000063-88

Full record on ClinicalTrials.gov

From the registry

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to 10 mg of Vortixetine and placebo in participants with major depressive disorder (MDD).

Primary outcomes

  • Change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at the End of the Double Blind Treatment Period (DBTP) (end of Week 6)

History

  1. Primary completion

  2. Last registry update

  3. Started

  4. Registered